Data showing the clinical outcomes of Samsung Bioepis’ biosimilar referencing Humira (adalimumab) were shared at the European Congress of Rheumatology’s annual meeting, EULAR 2022.
Samsung Bioepis shared new data from a phase 1 study and a real-world study showing the clinical outcomes associated with its adalimumab biosimilar (Imraldi; Hadlima; SB5), which references Humira, at the EULAR 2022 conference.
EULAR 2022 is the European Congress of Rheumatology’s annual meeting. It is being held in Copenhagen, Denmark, from June 1 through June 4. Imraldi was developed by Samsung Bioepis and Biogen and was approved for use in the European Union in August 2017.
“The addition of new data to our adalimumab biosimilar, SB5, is great news for patients with rheumatic and other inflammatory diseases….Samsung Bioepis has been constantly developing our data package for all our products and we are very pleased to be providing additional evidence which further demonstrates our dedication and commitment to providing quality biologic medicines,” said Donghoon Shin, vice president and medical and lifecycle safety team leader at Samsung Bioepis, in a company statement.
In the randomized, single-blind, 2-arm, parallel group, single-dose phase 1 study, the pharmacokinetics, safety, and tolerability profiles of the new formulation of SB5 (40 mg/0.4 mL) were compared with the original formulation (40 mg/0.8 mL) in healthy male participants. The results demonstrated the clinical equivalence between the 2 formulations.
The PROPER study was a pan-European real-world study sponsored by Biogen. The study was intended to provide insight into the outcomes related to switching from Humira to SB5. Overall, more than 1000 patients with rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, ulcerative colitis, or Crohn disease were enrolled after transitioning to the biosimilar after at least 16 weeks of treatment with the reference product.
Data on the patients were captured for 24 weeks prior to the transition through 48 weeks after switching to SB5. The study demonstrated that the effectiveness of adalimumab therapy remained after 48 weeks on the biosimilar, with most patients choosing to continuing treatment with SB5.
“We are very pleased with the results of the PROPER study which adds to the body of real-world evidence for our biosimilars, offering significant clinical insights for treatment optimization of patients with rheumatoid arthritis….Real-world evidence from studies like PROPER can provide meaningful insights on the use of anti-TNF biosimilars in clinical settings and can advance the understanding of their potential role in managing chronic immune mediated inflammatory diseases,” said Mourad Farouk Rezk, head of Global Medical and Development Biosimilars at Biogen.
SB5 was approved by the FDA in July 2019. When the biosimilar launches on the US market in July 2023, it will be marketed under the name Hadlima and it will be commercialized by Organon. Samsung Bioepis received the approval for a low-concentration formulation and a high-concentration, citrate-free formulation of Hadlima. SB5 was made available to patients in Australia in March 2021.
Samsung Biopeis and Biogen also share European commercialization rights for Benepali (etanercept biosimilar; SB4) and Flixabi (infliximab biosimilar; SB2).
Biosimilar Market Development Requires Strategic Flexibility and Global Partnerships
April 29th 2025Thriving in the evolving biosimilar market demands bold collaboration, early global partnerships, and a fresh approach to development strategies to overcome uncertainty and drive future success.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Unlocking Biosimilar Potential in Specialty Pharmacies With Legislative Support, Formulary Changes
April 24th 2025Sophia Humphreys, PharmD, MHA, BCBBS, emphasized that legislative support and formulary changes are crucial for overcoming unique challenges in specialty pharmacies and driving the growth of biosimilar adoption, which has significant cost saving potential in the next decade.
Decade of Biosimilars Yields $36 Billion in Savings and Strengthens Supply Chain
April 24th 2025Dracey Poore, MS, director of biosimilars and emerging therapies at Cardinal Health, highlighted that biosimilars saved $36 billion over the last decade by improving patient access and the supply chain, but continued education and a robust pipeline are crucial for future growth.